
Theses

2018

Assessment of the neuroprotective efficacy of poly-arginine-18 (R18) peptides in a pre-clinical model of perinatal hypoxic-ischaemic encephalopathy (HIE)

Adam Edwards
The University of Notre Dame Australia

Follow this and additional works at: <https://researchonline.nd.edu.au/theses>



COMMONWEALTH OF AUSTRALIA
Copyright Regulations 1969

WARNING

The material in this communication may be subject to copyright under the Act. Any further copying or communication of this material by you may be the subject of copyright protection under the Act.

Do not remove this notice.

Publication Details

Edwards, A. (2018). Assessment of the neuroprotective efficacy of poly-arginine-18 (R18) peptides in a pre-clinical model of perinatal hypoxic-ischaemic encephalopathy (HIE) (Doctor of Philosophy (College of Health Sciences)). University of Notre Dame Australia. <https://researchonline.nd.edu.au/theses/232>

This dissertation/thesis is brought to you by ResearchOnline@ND. It has been accepted for inclusion in Theses by an authorized administrator of ResearchOnline@ND. For more information, please contact researchonline@nd.edu.au.





THE UNIVERSITY OF
NOTRE DAME
A U S T R A L I A

**Assessment of the neuroprotective efficacy of
poly-arginine-18 (R18) peptides in a pre-clinical
model of perinatal hypoxic-ischaemic
encephalopathy (HIE)**

by

Mr Adam B. Edwards, BBioMedSc (Honours)

Thesis presented for the degree of Doctor of Philosophy

The University of Notre Dame Australia

School of Health Sciences

2018

ABSTRACT

Hypoxic-ischaemic encephalopathy (HIE) is one of the leading causes of mortality and morbidity in infants, globally. This disorder eventuates following a reduction in oxygenated cerebral blood flow to the foetus *in utero*, leading to excitotoxic-mediated brain cell (e.g. neuron, glia and glial progenitor cell) death. Currently, there is no clinically appropriate neuroprotective treatment to reduce acute brain injury following HIE. Recent studies have demonstrated that poly-arginine and cationic arginine-rich peptides (CARPs; e.g. R18: R = arginine residues) exhibit potent neuroprotective properties in both *in vitro* and adult animal models of ischaemia, and therefore have the potential to be developed into a neuroprotective treatment to reduce brain injury following HIE. Therefore, the aim of this thesis was to assess the neuroprotective efficacy of CARPs in a model of perinatal HIE in the rat.

To elucidate the neuroprotective efficacy of CARPs, a novel surgical modification to the original *in vivo* Rice-Vannucci model of perinatal HIE was developed. Using 7-day old Sprague-Dawley rats, brain injury was induced following the permanent ligation of the common and external carotid arteries, followed by a period of transient hypoxia (8% O₂/92% N₂). Results from this experiment demonstrated that the occlusion of common and external carotid arteries reduced cerebral communicational and/or anastomotic blood flow, reducing variability and improving the reliability in the presence of a cerebral infarct. The demonstration and termination of cerebral communicational and/or anastomotic blood flow improved the pre-clinical assessment of neuroprotective therapies to treat HIE.

The CARPs, R18, R18D (D-enantiomer) and JNKI-1-TATD, were assessed in the modified Rice-Vannucci model of HIE when administered intraperitoneally, immediately after the cessation of hypoxia-ischaemia (HI; 8% O₂/92% N₂ for 2.5 h). Treatment with R18 and R18D significantly reduced infarct volume and improved behavioural assessments in this model. Surprisingly, the well-characterised neuroprotective peptide JNKI-1-TATD, used as a positive control and benchmark, did not exhibit any significant neuroprotection. Succeeding positive results obtained following R18D administration immediately after HI, its therapeutic window was further assessed. R18D significantly decreased infarct volume and improved behavioural assessments when administered intraperitoneally up to 1 hour after the cessation of HI; correlating to 3.5 hours since HI onset. To confirm the neuroprotective mechanism of action of CARPs in HIE, an established *in vitro* primary cortical neuronal excitotoxic injury model was used. Results from this experiment demonstrate that CARPs reduce excitotoxic intracellular calcium influx in a dose-dependent fashion, providing evidence for a role in the reduction of several calcium-dependent pro-cell death cascades. The demonstration of significant neuroprotection following R18 peptide administration provides evidence for a novel therapeutic, which has the potential to reduce brain injury in infants who suffer HIE.

In summary, this thesis has identified a novel surgical modification to improve the reliability and reproducibility of the original Rice-Vannucci model of HIE. In addition, the administration of the R18 and R18D peptides following perinatal HIE, significantly reduces brain injury and improves behavioural assessments when administered up to 3.5 hours after the onset of HI. These findings demonstrate that CARPs provide an exciting and novel approach to reduce brain injury following HIE.

ACKNOWLEDGEMENTS

Firstly, I would like to express my sincere thanks and appreciation to my supervisors, Bruno Meloni, Ryan Anderton and Neville Knuckey, for without them, the work within this thesis would not have been possible. A special mention to Bruno Meloni, whose patience, wisdom and support extended far beyond my PhD, and for that, I cannot thank him enough.

To the staff and students of the Perron Institute, in particular the Stroke Research Group, the past 3.5 years have been incredibly enjoyable and everyone, in one way or another, has assisted me throughout my journey. A special mention to Frank Mastaglia whose poignant advice and knowledge was critical to my professional development.

To my two families, the Edwards' and the Frzop's, without your ears, your shoulders or your food, the journey throughout my PhD would have been a very different affair. In particular, to my parents, you gave me the opportunity of an education and taught me the importance of a strong work ethic, both of which were, and will continue to be paramount in my achievements within my PhD and beyond.

An extra special mention goes to my partner, Melissa. At every point along the winding road, you were there by my side. At times, it felt you knew more about my projects than I did. Thank you for being my grounding support and my tether to reality. Thank you for being you.

DECLARATION

I hereby declare that:

- This thesis is submitted as part of the requirement for a Doctor of Philosophy degree as a result of my own work and research. All other sources have been indicated and acknowledged.
- Permission has been granted by co-authors for any work that has been co-published to be included in this thesis.
- This thesis has been substantially completed during the course of enrolment and its content has not previously been submitted or accepted for any other degree in this or any other institution.
- I understand that this work may be electronically scanned for detection of plagiarism.

Signed.....

Adam B. Edwards

Signed.....

Coordinating Supervisor: Bruno Meloni

Approval of final thesis

PUBLICATIONS ARISING FROM THIS THESIS

Edwards A., Anderton R., Knuckey N., Meloni B. 2018. Review: Perinatal hypoxic-ischaemic encephalopathy and neuroprotective peptide therapies: a case for cationic arginine-rich peptides (CARPs). *Brain Sciences*, 7; 8 (8). doi: 10.3390/brainsci8080147.

Edwards A., Anderton R., Knuckey N., Meloni B. 2018. Assessment of therapeutic window for poly-arginine-18D (R18D) in a P7 rat model of perinatal hypoxic ischaemic encephalopathy. *Journal of Neuroscience Research*, 96 (11): 1816-1826. doi: 10.1002/jnr.24315.

Edwards A., Cross J., Anderton R., Knuckey N., Meloni B. 2018. Poly-arginine R18 and R18D (D-enantiomer) peptides reduce infarct volume and improves behavioural outcomes following perinatal hypoxic-ischaemic encephalopathy in the P7 rat. *Molecular Brain*, 11 (1): 8. doi: 10.1186/s13041-018-0352-0.

Edwards A., Feindel K., Cross J., Anderton R., Clark V., Knuckey N., Meloni B. 2017. Modification to the Rive-Vannucci perinatal hypoxic-ischaemic encephalopathy model in the P7 rat improves the reliability of cerebral infarct development after 48 hours. *Journal of Neuroscience Methods*, 288. doi: 10.1016/j.jneumeth.2017.06.016.

CONFERENCE PROCEEDINGS ARISING FROM THIS THESIS

Edwards A., Anderton S., Knuckey N., Meloni B. 2017. *The poly-arginine-18 (R18) peptide is neuroprotective in a modified model of perinatal hypoxic-ischaemic encephalopathy; a dose-response and therapeutic window study.* Oral presentation at: Combined Biological Sciences Meeting; Perth, Australia.

Edwards A., Feindel K., Cross J., Anderton R., Clark V., Knuckey N., Meloni B. 2017. Neuroprotective efficacy of poly-arginine-18 (R18) peptides using an *in vivo* model of perinatal hypoxic-ishaemic encephalopathy. *Journal of Cerebral Blood Flow and Metabolism*, 37 (IS) 1-97. doi: 10.1177/0271678X17695978.

Edwards A., Feindel K., Cross J., Anderton R., Clark V., Knuckey N., Meloni B. 2017. Neuroprotective efficacy of poly-arginine-18 (R18) peptides using an *in vivo* model of perinatal hypoxic-ishaemic encephalopathy. Oral presentation at: Berlin Brain, 28th Symposium of Cerebral Blood Flow, Metabolism and Function; Berlin, Germany.

Edwards A., Anderton R., Knuckey N., Meloni B. 2016. *Babies' brains matter too.* Oral presentation: 3-minute thesis, 10th Federation of European Neurosciences Societies (FENS) Forum of Neuroscience; Copenhagen, Denmark.

Edwards A., Anderton R., Knuckey N., Meloni B. 2016. *Neuroprotective efficacy of poly-arginine peptides using an in vitro excitotoxicity model; implications for therapeutics.* Poster presentation at: 10th Federation of European Neurosciences Societies (FENS) Forum of Neuroscience; Copenhagen, Denmark.

Edwards A., Cross J., Anderton R., Knuckey N., Meloni B. 2016. *Neuroprotective efficacy of poly-arginine peptides using an in vitro model of neonatal hypoxic-ischaemic encephalopathy.* Poster presentation at: Combined Biological Sciences Meeting; Perth, Australia.

AWARDS ARISING FROM THIS THESIS

Fee Remission Postgraduate Scholarship

The University of Notre Dame Australia;

Fremantle, Australia (2015 – 2018).

University Postgraduate Award

The University of Notre Dame Australia;

Fremantle, Australia (2015 – 2018).

Young Investigator Travel Programme Award

10th Federation of European Neurosciences Societies (FENS) Forum of
Neuroscience;

Copenhagen, Denmark (2016).

Student Oral Presentation Prize

Combined Biological Sciences Meeting (CBSM);

Perth, Australia (2017).

Berlin Brain Travel Bursary

Berlin Brain and Brain Positron Emission Tomography Conference;

Berlin, Germany (2017)

Student Poster Prize

Science on the Swan;

Fremantle, Australia (2018).

Student Oral Presentation Prize

Science on the Swan;

Fremantle, Australia (2018).

TABLE OF CONTENTS

List of abbreviations	xx
List of figures	xxiii
List of tables.....	xxv
Chapter 1 – General Introduction	1
Introduction	2
Perinatal hypoxic-ischaemic encephalopathy	3
<i>Epidemiology</i>	3
<i>Aetiology</i>	3
<i>Clinical aspects</i>	5
Pathophysiology.....	6
<i>Necrosis</i>	6
<i>Apoptosis</i>	7
<i>Excitotoxicity</i>	7
<i>Oxidative stress</i>	8
<i>Mitochondrial dysfunction</i>	8
<i>Inflammation</i>	9
Current acute clinical neuroprotective treatment	9
<i>Hypothermia</i>	9
Other clinical neuroprotective approaches under consideration	11
<i>Xenon</i>	11
<i>Topiramate</i>	12

<i>Pre-term therapeutic hypothermia</i>	12
<i>Antenatal magnesium sulfate (MgSO₄)</i>	13
<i>Erythropoietin (EPO) and darbepoetin adjuvant to hypothermia</i>	14
CARPs and neuroprotection.....	15
Aims of the thesis.....	14
References	17
Chapter 2 – Perinatal hypoxic-ischaemic encephalopathy and neuroprotective peptide therapies: a case for cationic rich arginine peptides (CARPs)	33
Author contributions	34
Abstract	35
Introduction	35
Pathophysiology of perinatal hypoxic-ischaemic brain injury.....	36
<i>Initiation of the pathophysiological cascade in HIE</i>	36
<i>Excitotoxicity</i>	37
<i>Oxidative stress</i>	37
<i>Mitochondrial dysfunction</i>	37
<i>Inflammation</i>	38
Current clinical treatments: hypothermia.....	38
Neuroprotective peptides and their therapeutic application in HIE	39
<i>Peptide therapeutics</i>	39
<i>Cationic arginine-rich peptides are intrinsically neuroprotective</i>	39

<i>Cationic arginine-rich cell penetrating peptide neuroprotective mechanisms of actions</i>	40
Studies using CARPs in animal models of HIE.....	41
<i>TAT-NEMO Binding Domain (NBD)</i>	41
<i>TAT-mGluR1</i>	42
<i>c-Jun N-terminal kinase (JNK) inhibitors</i>	42
<i>TAT-BH4</i>	43
<i>Osteopontin (OPN) and TAT-fused OPN peptide (TAT-OPN)</i>	43
<i>P5-TAT</i>	44
<i>D-TAT-GESV</i>	44
<i>TAT-NR2B9c/NA-1</i>	44
<i>Poly-arginine-18 (R18 and R18D)</i>	45
Other peptides examined in animal models of HIE	45
<i>COG133</i>	45
<i>Connexin 43 (Cx43) derived peptides</i>	45
<i>Apelin-36</i>	46
<i>Innate defense regulator (IDR) peptide IDR-1018</i>	46
Do all CARPs including TAT-fused peptides share a common neuroprotective mechanism of action?.....	49
Conclusions	49
Future directions.....	50
Acknowledgements	50

Author contributions	50
Conflict of interest.....	50
References	50
Chapter 3 – General Materials and Methods	61
Materials and methods	62
Peptides used in this thesis.....	62
P7 rat models of hypoxic-ischaemic encephalopathy	63
<i>Animal ethics approval</i>	63
<i>Animal numbers used in experimentation</i>	63
<i>Behavioural assessments</i>	64
Righting reflex	64
Negative geotactic response.....	64
Wire-hang assessment.....	65
<i>Original Rice-Vannucci HI surgical procedure</i>	65
<i>Modified Rice-Vannucci HI surgical procedure</i>	66
<i>Post-surgical analgesia, animal body temperature monitoring and housing</i>	67
<i>Ex vivo</i> assessment of brain injury	67
<i>Tissue sectioning and triphenyl tetrazolium chloride (TTC) staining</i>	67
Measurement of infarct volume from TTC stained coronal slices	68
Statistical analysis	68
References	69

Chapter 4 – Modification to the Rice-Vannucci perinatal hypoxic-ischaemic encephalopathy model in the P7 rat improves the reliability of cerebral infarct development after 48 hours	70
Author contributions	71
Abstract	72
Introduction	72
Materials and methods	73
<i>Rice-Vannucci and modified HIE surgical models</i>	73
<i>Infarct volume assessment</i>	73
<i>Functional testing</i>	74
<i>Magnetic resonance imaging</i>	74
<i>Processing of FAIR-EPI data</i>	75
<i>Statistical analysis</i>	75
Results	75
<i>Time-of-flight magnetic resonance angiography (TOF-MRA)</i>	75
<i>Phase-contrast velocity encoding</i>	76
<i>Pulsed arterial spin labelling (PASL)</i>	76
<i>Infarct volume measurements after HIE</i>	76
<i>Functional outcomes after HIE</i>	78
Discussion	78
Conclusion	79

Author’s contributions	79
Competing interests.....	80
Acknowledgments.....	80
Appendix A. supplementary data.....	80
References	80
Supplementary data.....	82
Chapter 5 – Poly-arginine R18 and R18D (D-enantiomer) peptides reduce infarct volume and improves behavioural outcomes following perinatal hypoxic-ischaemic encephalopathy in the P7 rat.....	85
Author contributions	86
Abstract	87
Introduction.....	87
Materials and methods	88
<i>Animal ethics and study design</i>	88
<i>Peptides used in the study</i>	88
<i>Surgical procedure for modified Rice-Vannucci model</i>	89
<i>Peptide administration</i>	89
<i>Animals used and sample size</i>	89
<i>Infarct volume assessment</i>	89
<i>Behavioural assessment</i>	90
<i>Cortical neuronal cultures</i>	90

<i>Glutamic acid excitotoxicity</i>	90
<i>Intracellular calcium kinetics</i>	91
<i>Statistical analysis</i>	92
Results	92
<i>Infarct volume measurements</i>	92
<i>Behavioural outcomes, weight gain and gender analysis</i>	92
<i>In vitro neuroprotective efficacy and calcium kinetics following glutamic acid excitotoxicity</i>	94
Discussion	95
Additional files	96
Abbreviations	96
Acknowledgments	96
Funding	96
Availability of data and materials	96
Authors' contributions	96
Ethics approval and consent to participate	96
Consent for publication	96
Competing interests	97
Publishers' note	97
Author details	97
References	97
Supplementary data	99

Chapter 6 – Assessment of therapeutic window for poly-arginine-18D (D-enantiomer) in a P7 rat model of perinatal hypoxic-ischaemic encephalopathy	105
.....	
Author contributions	106
Abstract	107
Introduction	107
Significance.....	108
Materials and methods	108
<i>Peptides used in the study</i>	108
<i>Animal ethics and study design</i>	108
<i>Surgical procedure for modified Rice-Vannucci model</i>	109
<i>Post-surgical analgesia and monitoring</i>	109
<i>Peptide administration</i>	109
<i>Animals used and sample size</i>	109
<i>Infarct volume assessment</i>	109
<i>Behavioural assessments</i>	109
<i>Statistical analysis</i>	110
Results	113
<i>Infarct volume measurements</i>	113
<i>Behavioural outcomes following R18D administration</i>	113
Discussion	113
Limitations of study	115

Conclusion	115
Acknowledgments.....	115
Author contributions	115
Data accessibility	115
Competing interests.....	115
Author contributions	115
Data accessibility	115
ORCID	115
References	115
Supplementary data.....	118
Chapter 7 – General discussion	124
Introduction	125
Key findings arising from this thesis	127
<i>Cerebral collateral circulation and infarct volume variability</i>	127
<i>Effectiveness of R18 and R18D in a perinatal HIE model</i>	129
Limitations of this thesis	131
Summary of important findings of study	134
References	136

LIST OF ABBREVIATIONS

AMPA	α -amino-3-hydroxy-5-methyl-4-isoxazolepropionic acid
ANOVA	Analysis of variance
ATP	Adenosine triphosphate
AUC	Area under the curve
BSS	Balanced salt solution
CARP	Cationic arginine-rich peptide
CBF	Cerebral blood flow
CCA	Common carotid artery
CCAO	Common carotid artery occlusion
CPP	Cell penetrating peptide
DNA	Deoxyribonucleic acid
ECA	External carotid artery
ECAO	External carotid artery occlusion
EPO	Erythropoietin
FAIR	Fluid attenuation inversion recovery
GABA	γ -aminobutyric acid
HI	Hypoxic-ischaemic or hypoxia-ischaemia
HIE	Hypoxic-ischaemic encephalopathy
ICA	Internal carotid artery

ICV	Intracerebroventricular
IL	Interleukin
IP	Intraperitoneal
IV	Intravenous
LPS	Lipopolysaccharide
MCAO	Middle cerebral artery occlusion
MEM	Minimum essential medium
MgSO₄	Magnesium sulfate
MMP	Matrix metalloproteinase
MPTP	Mitochondrial permeability transition pore
MRA	Magnetic resonance angiography
MRI	Magnetic resonance imaging
MTS	3-(4, 5, dimethyliazol-2-yl)-5-(3-carboxymethoxy-phenyl)-2-(4-sulfophenyl)-2H-tetrazolium salt
NMDA	N-methyl-D-aspartic acid
P7	7-day-old
PASL	Pulsed arterial spin labelling
ROS	Reactive oxygen species
SD	Sprague-Dawley
SE-EPI	Spin-echo echo-planar imaging

TOF Time of flight

TTC Triphenyl tetrazolium chloride

LIST OF FIGURES

Figure 4.1 Diagrammatic representation of communicational and anastomotic blood flow for CCA occlusion and CCA/ECA occlusive surgical procedures.....	75
Figure 4.2 Maximum intensity projections of time-of-flight magnetic resonance angiography depicting arterial flow from caudal to rostral direction in sham, CCA occlusion, or CCA/ECA occlusion animals	76
Figure 4.3 Velocity analysis of blood through the pre- and post-bifurcated left and right CCA.....	77
Figure 4.4 Cerebral blood flow (CBF) (mL/100 g/min) measured by PASL	78
Figure 4.5 Infarct volume analysis, representative images of coronal brain slices, and behavioural assessment 48 h after hypoxic-ischaemic insult.....	79
Figure 4.6 Infarct volume analysis, representative images of coronal brain slices, and behavioural assessment of ischaemic (CCA or CCA/ECA occlusion) or hypoxic-ischaemic (CCA/ECA occlusion and hypoxia) injury 48 hours after insult	80
Figure 4.7 Grayscale 2D, T2-weighted RARE slices in the (a) sagittal and (b) coronal plane demonstrating the 1mm ASL slice positioning in Figure 4 (red bar; to scale). 83	
Figure 4.8 Grayscale T1-weighted slice in the coronal plane.....	84
Figure 5.1 Percentage infarct volume; percentage infarct volume, representative images of coronal brain slices and percentage infarct volume in brain slices for the different treatment groups as determined 48 h after HI	91
Figure 5.2 Behavioural measurements using righting reflex, negative geotactic response, wire-hang test and weight gain 48 h after HI.....	93

Figure 5.3 Glutamic acid excitotoxicity model; R18, R18D and JNKI-1-TATD dose response study	94
Figure 5.4 Intracellular calcium assessment using Fura-2 AM after glutamic acid exposure in primary neuronal cultures	95
Figure 5.5 Comparison of percentage total infarct volume in male and female animals with R18, R18D or saline.....	104
Figure 6.1 Schematic representation followed for R18D neuroprotective study in a perinatal rodent model of hypoxic-ischaemic encephalopathy	110
Figure 6.2 Assessment of R18D when administered 30 min after the conclusion of hypoxia.....	111
Figure 6.3 Assessment of R18D when administered 60 min after the conclusion of hypoxia.....	112
Figure 6.4 Assessment of R18D when administered 120 min after the conclusion of hypoxia.....	114

LIST OF TABLES

Table 1.1 Risk factors associated with HI.....	4
Table 1.2 Sarnat staging for diagnosis of HIE severity.....	6
Table 2.1 Studies using CARPs and other peptides examined in animal models of HIE	47
Table 3.1 Summary of the peptides used in this thesis	62
Table 4.1 Proposed sources of infarct variability within Rice-Vannucci HIE model	74
Table 4.2 All RF pulsed were automatically calculated with ParaVision 6.0.1 based on Shinnar-Le Roux (SLR) algorithm	82
Table 5.1 Peptides used in this study	89
Table 5.2 Animals excused in the study.....	90
Table 5.3 Cerebral infarct. Percentage of total cerebral volume.....	92
Table 5.4 Cerebral infarct. Percentage of topographical coronal slices	99
Table 5.5 Behavioural assessment.....	101
Table 5.6 Weight gain 48 hours after hypoxia-ischaemia.....	103
Table 6.1 Animals excluded in the study	118
Table 6.2 Cerebral infarct. Percentage of total cerebral volume.....	119
Table 6.3 Behavioural assessment; treatment 30 min post-HI.....	120
Table 6.4 Behavioural assessment; treatment 60 min post-HI.....	121
Table 6.5 Behavioural assessment; treatment 120 min post-HI.....	122
Table 6.6 Weight gain from baseline to 48 h post-HI.....	123